|
Stryker has invested over 20 years of in developing Osigraft (eptotermin alfa), a naturally occurring osteoinductive protein that has demonstrated the ability to stimulate, repair and regenerate bone. Stryker offers Osigraft fo a trauma indication “Treatment of nonunion of tibia of at least 9 months duration, secondary to trauma, in skeletally mature patients, in cases where previous treatment with autograft has failed or use of autograft is unfeasible.” Osigraft is a medicinal product subject to restricted medical prescription. For more information connect to the Osigraft dedicated website: www.osigraft.eu | |||||